Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (COMRADE)
NCT03317392Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in castration-resistant prostate cancer (CRPC), sponsored by National Cancer Institute. Started Feb 2019; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03317392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317392.